Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYin WuCYChenglu YuanYCYuqing Chen

Discussion

Loading...

Member takes

Overview

Prospective clinical study shows golidocitinib improved outcomes in relapsed/refractory T cell leukemia, highlighting safety profile.

Key Points

  • To evaluate the efficacy and safety of golidocitinib in patients with relapsed/refractory T/NK large granular lymphocyte leukemia.
  • Open-label, prospective clinical study
  • Patients received oral golidocitinib 150 mg once daily
  • Primary endpoint is objective response rate (ORR)
  • Data reported from T-LGLL cohort
  • 16 relapsed/refractory T or NK LGLL patients enrolled
  • 92.3% ORR among efficacy evaluable patients
  • 61.5% achieved hematologic complete response
  • Neutrophil counts normalized in 88.9% of neutropenic patients
  • Adverse events reported in 12% of patients, all resolved

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1echttps://doi.org/10.1182/blood-2025-3648
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Golidocitinib was used for the first time to treat refractory NK-Large Granular lymphocytic leukemia with a STAT3 mutation, accompanied by hemolytic anemia: a case report.2025 · 3 citations
  2. 2Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025
  3. 3Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib2025
  4. 4Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study2025 · 1 citations
  5. 5Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial2025 · 1 citations